8.5K
Articles
275.5K
Citations
3.4
avg. Impact Factor
208
h-index

Most Cited Articles of Department of Radiation Oncology in 2017

TitleJournalYearCitations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet, The20171.2K
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationNew England Journal of Medicine20171.1K
Association analysis identifies 65 new breast cancer risk lociNature2017643
Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell2017511
Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupLancet Oncology, The2017275
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular ProfilesCell Reports2017247
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyJournal of Clinical Oncology2017246
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLBlood2017244
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman diseaseBlood2017234
A novel community driven software for functional enrichment analysis of extracellular vesicles dataJournal of Extracellular Vesicles2017200
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) AntibodiesJAMA Neurology2017179
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerClinical Cancer Research2017160
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsPancreas2017152
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian CancerJAMA Oncology2017152
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon CancerJournal of the National Cancer Institute2017138
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialLancet Haematology,the2017137
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesBlood2017134
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved MechanismsJournal of Clinical Endocrinology and Metabolism2017125
Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast CancerClinical Cancer Research2017119
Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma SubcommitteeInternational Journal of Radiation Oncology Biology Physics2017111
Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institutionSurgical Endoscopy and Other Interventional Techniques2017103
A conserved NAD binding pocket that regulates protein-protein interactions during agingScience2017102
Genomic Profiling of Small-Bowel AdenocarcinomaJAMA Oncology2017101
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideBlood2017101
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1αClinical Cancer Research2017101